Market capitalization | $31.34b |
Enterprise Value | $31.44b |
P/E (TTM) P/E ratio | 48.10 |
EV/FCF (TTM) EV/FCF | 58.77 |
EV/Sales (TTM) EV/Sales | 7.95 |
P/S ratio (TTM) P/S ratio | 7.93 |
P/B ratio (TTM) P/B ratio | 15.84 |
Revenue growth (TTM) Revenue growth | 16.19% |
Revenue (TTM) Revenue | $3.95b |
Set up alerts on Stock Price, Dividend Yield, Valuation (e.g. P/E or EV/Sales) or Strategy Scores and sit back and relax.
26 Analysts have issued a DexCom, Inc. forecast:
26 Analysts have issued a DexCom, Inc. forecast:
Sep '24 |
+/-
%
|
||
Revenue | 3,954 3,954 |
16%
16%
|
|
Gross Profit | 2,441 2,441 |
13%
13%
|
|
EBITDA | 840 840 |
24%
24%
|
EBIT (Operating Income) EBIT | 628 628 |
24%
24%
|
Net Profit | 681 681 |
81%
81%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
DexCom, Inc. is a medical device manufacturing company. The firm engages in the design, development and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. Its products include Dexcom G4 PLATINUM System, DexCom G5 Mobil, DexCom Share and Mobile apps. The company was founded by John F. Burd on May 1, 1999 and is headquartered in San Diego, CA.
Head office | United States |
CEO | Kevin Sayer |
Employees | 9,600 |
Founded | 1999 |
Website | www.dexcom.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.